Syndax Pharmaceuticals reported third-quarter revenue of $83.3 million, driven by $60.7 million in Revuforj net sales and $22.6 million in Niktimvo collaboration revenue. The company appointed Aaron A. Ondrey as Chief Financial Officer effective November 9, 2026, succeeding retiring CFO Keith Goldan. Ondrey receives a $543,000 base salary and a one-time option grant of 270,000 shares. Syndax is a commercial-stage biopharmaceutical company advancing innovative cancer therapies.
